Special Drug Use-Results Survey of Evaluating Safety and Effectiveness of Humira in Long Term Treatment in Patients With Hidradenitis Suppurativa
Latest Information Update: 19 Apr 2022
At a glance
- Drugs Adalimumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Adverse reactions
- Sponsors AbbVie
- 01 Apr 2022 12 week interim effectiveness results published in the Journal of Dermatology
- 14 Jan 2022 Status changed from recruiting to completed.
- 28 May 2019 Status changed from not yet recruiting to recruiting.